Dr. Zsiros Discusses Pembrolizumab Triplet in Recurrent Ovarian Cancer

Emese Zsiros, MD, PhD
Published: Monday, Mar 18, 2019



Emese Zsiros, MD, PhD, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, discusses results of a phase II trial evaluating the use of pembrolizumab (Keytruda) in combination with bevacizumab (Avastin) and oral metronomic cyclophosphamide for the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

In the study, pembrolizumab was administered at 200 mg intravenously (IV) in combination with bevacizumab at 15 mg/kg IV every 3 weeks, plus oral cyclophosphamide at 50 mg daily until patients experienced either disease progression or unacceptable toxicity.

Interim results of the open-label clinical trial, which were presented at the 2019 SGO Annual Meeting, demonstrated that the triplet combination elicited an overall response rate of nearly 40% in this group of heavily pretreated patients with platinum-resistant recurrent ovarian cancer; 16 out of 40 patients had a partial response, and 2 of these patients had a near complete response, Zsiros says. Additionally, 55% of patients had stable disease, and the disease control rate was 95%, she adds.

Regarding safety, the 3-drug combination was well tolerated, and the most common grade 3 adverse events were decreased lymphocyte count and hypertension.

<<< 2019 SGO Annual Meeting


Emese Zsiros, MD, PhD, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, discusses results of a phase II trial evaluating the use of pembrolizumab (Keytruda) in combination with bevacizumab (Avastin) and oral metronomic cyclophosphamide for the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

In the study, pembrolizumab was administered at 200 mg intravenously (IV) in combination with bevacizumab at 15 mg/kg IV every 3 weeks, plus oral cyclophosphamide at 50 mg daily until patients experienced either disease progression or unacceptable toxicity.

Interim results of the open-label clinical trial, which were presented at the 2019 SGO Annual Meeting, demonstrated that the triplet combination elicited an overall response rate of nearly 40% in this group of heavily pretreated patients with platinum-resistant recurrent ovarian cancer; 16 out of 40 patients had a partial response, and 2 of these patients had a near complete response, Zsiros says. Additionally, 55% of patients had stable disease, and the disease control rate was 95%, she adds.

Regarding safety, the 3-drug combination was well tolerated, and the most common grade 3 adverse events were decreased lymphocyte count and hypertension.

<<< 2019 SGO Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x